Νέα

Gene-editing Therapy CTX-001 Granted Priority Medicines Designation for Severe SCD in EU

Gene-editing Therapy CTX-001 Granted Priority Medicines Designation for Severe SCD in EU

CTX001, an investigational gene-editing cell therapy, has been granted priority medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of severe sickle cell disease (SCD). The announcement was made by CRISPR Therapeutics and Vertex Pharmaceuticals, which are jointly…
Iranian Blood Transfusion Organization Newsletter

Iranian Blood Transfusion Organization Newsletter

The Iranian Blood Transfusion Organization (IBTO) and its most recent activities are featured on TIF’S website.
COVID-19 Update: Here’s Where We Stand Now In the Race For A Vaccine

COVID-19 Update: Here’s Where We Stand Now In the Race For A Vaccine

As large parts of the world prepare for a second wave of coronavirus cases governments have pinned their hopes on the rapid development of a vaccine to provide a route…
eThalED Webinar Series: Heart Disease in Thalassaemia

eThalED Webinar Series: Heart Disease in Thalassaemia

Last -but not least- in our eThalED Webinar Series for Medical Specialists comes ‘Heart Disease in Thalassaemia’, one the major causes of morbidity and mortality among patients with this severe…
TIF’s Latest Newsletter Issue Is Out!

TIF’s Latest Newsletter Issue Is Out!

Our August 2020 newsletter has just been published! Read about our latest updates, including country activities, international projects, educational updates for patients with thalassaemia and haemoglobin disorders, and our novel…
Revisiting The Use and Management of Blood in Europe in Times of Crisis and Beyond

Revisiting The Use and Management of Blood in Europe in Times of Crisis and Beyond

About 25 million blood transfusions are administered to patients every year throughout the European Union. What may come to mind to most people when thinking about blood transfusion is acute…
AstraZeneca Resumes Final Stage Trials For Its Covid-19 vaccine After Initial Halt

AstraZeneca Resumes Final Stage Trials For Its Covid-19 vaccine After Initial Halt

AstraZeneca Plc and the University of Oxford have resumed the British clinical trials of its Covid-19 vaccine, after the initial suspension over concerns with a participant who fell ill. University…
The ”International Blood Diseases Symposium” Is Just Around The Corner

The ”International Blood Diseases Symposium” Is Just Around The Corner

The Turkish Federation of Blood Diseases, Kan Hastalıkları Federasyonu  is joining forces with TIF for the organisation of the ”International Blood Diseases Virtual Symposium”, which will be held virtually on…
Coming Up: A TIF Live Webinar on ”Heart Disease in Thalassaemia”

Coming Up: A TIF Live Webinar on ”Heart Disease in Thalassaemia”

Tune in with TIF on Tuesday, 15 September 2020, 15:00 EEST, for one of the last webinars from the TIF eThalED series for Healthcare Professionals! The topic to be brought…
AstraZeneca Puts Leading COVID-19 Vaccine Trial On Hold

AstraZeneca Puts Leading COVID-19 Vaccine Trial On Hold

The pharmaceutical company AstraZeneca halted large, late-stage global trials of its coronavirus vaccine on Tuesday, because of a serious suspected adverse reaction in a participant. It is not yet known…
Back to top button